Hamps Bio Limited Management Discussions

ANNEXURE-V

Your directors take pleasure in presenting the Management Discussion and Analysis Report for the year ended March 31, 2025.

Hamps Bio Limited, incorporated in 2007, began its journey with a focus on ethical pharmaceutical product marketing, supported by a strong distribution network. In 2017, the Company strategically diversified into the freeze-dried food and nutraceutical ingredients sector, marking a significant turning point in its growth trajectory. With innovation, sustainability, and manufacturing expansion at its core, Hamps Bio has steadily evolved into a prominent player in the freeze-drying industry.

The Companys business is structured around the production of high-quality freeze-dried ingredients for both domestic and international markets. A new manufacturing unit at Bhatpore, Surat has been fully set up, with the completion of all plant setup processes including equipment purchase, machinery installation, and commercial trial runs. This addition, alongside the operational unit at Ankleshwar, positions the Company for increased production efficiency and scalability. These facilities support a strategic expansion plan aimed at meeting growing global demand

Hamps Bio Limited, originally incorporated as Hamps Bio Private Limited on January 2, 2007, transitioned to a public limited company and was listed on the SME Platform of the BSE on December 20, 2024. This transition reflects the Companys long-term vision to enhance operational capabilities and uphold high standards of corporate governance.

The Companys growth has been guided by its founders, Mr. Herrik Mountbaton Shah and Mr. Shrenikkumar Mountkumar Shah, whose combined leadership has driven Hamps Bio to establish a solid presence in both the freeze-drying and pharma marketing sectors.

With over two decades of experience, Mr. Herrik Shah, in particular, has been instrumental in shaping the Companys success through his deep expertise in freeze-drying technology, nutraceutical innovation, and international business strategy.

Specialization in developing scalable and sustainable production models in the freeze- dried ingredient segment with a focus on export-quality standards.

Instrumental in leading the company from a single-location manufacturing unitto a multilocation production ecosystem with facilities in Ankleshwar and Surat

Initiated the green energy transition through the procurement of equipment and execution of key agreements for a 350 kVA ground-mounted solar plant, reinforcing the companys commitment to sustainability.

Successfully led Hamps Bio Limited through its IPO in December 2024, ensuring compliance, transparency, and strong investor confidence.

Operational Structure

The corporate office serves as the nerve centre for strategic planning, finance, investor relations, export documentation, legal and compliance activities, and overall corporate governance.

a. Ankleshwar Plant (Existing Unit):

• Activity: Commercial production of freeze-dried products

• Capacity: 18 tons/month

• Specialization: Vegetables, herbs, and ready-to-eat ingredients

• Sustainability: Powered partly by a 350 kVA solar plant process initiated.

• Status: Plant setup process initiated, including purchase of machinery, installation, and completion of commercial trials

• Planned Capacity: 7 tons/month (initial phase), with a planned increase of 3 tons after six months of commercial operations

• Focus: Designed to meet the growing global export demand through advanced freezedrying production capabilities

Focused on the manufacturing and export of freeze-dried fruits, vegetables, herbs, and ready-to-eat ingredients, this division operates across both Ankleshwar and projected Surat units. With upcoming solar-powered infrastructure and export-centric production, the division adheres to international quality standards and sustainability practices.

This division emphasizes ethical marketing of pharmaceutical products through a growing Medical Representative (MR) network. It focuses on chronic therapies and nutraceuticals, with continued investment in brand building and market penetration. Post-IPO, it plays a key role in revenue diversification and long-term growth.

The global demand for clean-label, natural, and long-shelf-life food products has accelerated the growth of the freeze-dried food industry. In India and abroad, the nutraceutical and wellness sectors are growing at an annual rate of 12-15%, presenting strong export opportunities for high- quality freeze-dried ingredients.

The freeze-drying industry is also seeing increased application in pharmaceutical intermediates and ready-to-eat health foods, supported by sustainable production technologies.

Key Developments

• Increased focus on B2B ingredient supply to global partners

• Upcoming Green energy adoption through solar infrastructure

• Capacity expansion with IPO proceeds

• Investment in digital traceability and automation SWOT Analysis

Hamps Bio Limited operates under a robust compliance framework aligned with applicable regulatory standards. The Company has implemented comprehensive Standard Operating Procedures (SOPs) that ensure ethical practices, client confidentiality, and data protection.

A dedicated internal audit team conducts regular reviews across departments to maintain operational integrity and regulatory compliance. In addition, ongoing training programs for staff and field teams reinforce adherence to the Code of Conduct, RBI guidelines, fair practices, and client data protection protocols.